Clinical Trial Update: A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP) [Phase 4]

View source ↗

Summary

A Phase 4 randomized, placebo-controlled trial evaluating DAPAgliflozin for cardiovascular risk reduction in the postpartum period after hypertensive pregnancie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Gestational Hypertension
• Hypertension in Pregnancy
• Preeclampsia
• Superimposed Preeclampsia

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: University of Michigan | Conditions: Gestational Hypertension, Hypertension in Pregnancy | Phase 4 | Status: RECRUITING